Characterisation of Endothelial Cells in Different Inflammatory Pathologies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Endothelial cell biopsy.
- Who it may be relevant to
- Registry conditions: Sepsis, Vasoplegia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery. The main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'
Detailed description
The immune system is a complex network of cells and molecules that protects the body from infection and injury. When the immune system is activated, it produces inflammation, which is a natural response to help heal the body. However, too much inflammation can be harmful and lead to serious complications, such as sepsis, low blood pressure, organ failure and death.
The interaction of cells that line the blood vessels (endothelial cells, EC) with the immune system, is believed to be the root cause of these symptoms. When exposed to inflammation, the instructional molecules (RNA) inside the EC change. This leads to a change of operation promoting the severe symptoms previously mentioned.
Researchers have developed new safe techniques to collect these cells from the blood vessels of patients to study disorders like diabetes, heart disease and stroke. This technique involves gently inserting a metal guidewire into an arm vein to collect ECs.
This study plans to collect ECs from patients undergoing surgery or admitted to intensive care. We also plan to collect control samples from healthy volunteers. Samples will be collected over the duration of the patients to RSFT. The RNA will be removed from the cells and counted to highlight changes in instructions in the cells.
Data from this study will potentially highlight new pathways involved in inflammation and help classify how some patients will react to current treatments. To obtain this data, this study will be split into 2 parts. Part 1 focuses on collecting one sample from a patient when they are at their most unwell states and comparing that to a sample from a healthy person. Part 2 will focus on key mRNA molecules identified during Part 1 and identifying how their expression changes over time.
Interventions
- Other Endothelial cell biopsy
Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
Primary outcome measures
- Differential gene expression in endothelial cells [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
Healthy volunteer
- Adult ≥ 18 years
- Able and willing to give consent
Surgical patients
- Adult ≥ 18 years
- Patients admitted to RSFT for planned major surgery
Critically ill patients
- Adult ≥ 18 years
- Emergency admission to ICU at RSFT
- Meets the sepsis 3.0 definition
Exclusion criteria
Healthy volunteer
- Not currently a patient within the hospital
- Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD.
- Not on immunomodulatory medications, such as corticosteroids
- History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
Surgical patients
- Patients with restricted liberty, prisoners or under legal protection
- Anticipated prohibitively difficult venous cannulation
- Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD
- Currently prescribed immunomodulatory medication or immunocompromised
- Received chemotherapy within 2 weeks of predicted sampling
- Receiving vasopressor support prior to surgery
- History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
Critically ill patients
- Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation
- Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD.
- Currently prescribed immunomodulatory medication or immunocompromised
- Received chemotherapy within 2 weeks of predicted sampling.
- History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- Royal Surrey NHS Foundation Trust — Guildford
Identifiers
NCT: NCT06613256 · 24SURN320251